Vestcor Inc Seagen Inc. Transaction History

Vestcor Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $5.78 Million - $6.52 Million	30,175 Added 180.39%	46,903 $9.95 Million
Q2 2023 Aug 15, 2023	BUY	$187.64 - $206.25 $2.53 Million - $2.78 Million	13,464 Added 412.5%	16,728 $3.22 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $1.58 Million - $2.52 Million	-12,389 Reduced 79.15%	3,264 $661,000
Q4 2022 Feb 15, 2023	BUY	$117.37 - $139.17 $1.46 Million - $1.73 Million	12,401 Added 381.33%	15,653 $2.01 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $6,357 - $8,465	47 Added 1.47%	3,252 $445,000
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $112,727 - $185,785	1,036 Added 47.76%	3,205 $567,000
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $58,010 - $76,557	485 Added 28.8%	2,169 $312,000
Q4 2021 Feb 15, 2022	SELL	$142.57 - $190.86 $46,905 - $62,792	-329 Reduced 16.34%	1,684 $260,000
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $37,891 - $45,172	-266 Reduced 11.67%	2,013 $342,000
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $307,847 - $367,146	2,279 New	2,279 $360,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Vestcor Inc, based on Form 13F filings with the SEC.

Stay updated on Vestcor Inc with notifications on news.